trending Market Intelligence /marketintelligence/en/news-insights/trending/cWa-r_IGqKdCjNMmuC7Z8Q2 content esgSubNav
In This List

Ionis earns $10M milestone payment from Biogen for Alzheimer's study

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Ionis earns $10M milestone payment from Biogen for Alzheimer's study

Ionis Pharmaceuticals Inc. said it earned a $10 million milestone payment from Biogen Inc. upon initiation of the phase 1/2a trial of IONIS-MAPT in patients with mild Alzheimer's disease.

Ionis and Biogen are jointly developing novel therapies, such as the antisense drug Spinraza, to treat neurological disorders.

Under their partnership, the companies are developing IONIS-SOD1 for amyotrophic lateral sclerosis, as well as IONIS-BIIB5, IONIS-BIIB6 and IONIS-BIIB7 for undisclosed neurodegenerative diseases.